Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?
Alnylam Pharmaceuticals, the pharma market’s leader in RNAi therapies, reported its third quarter earnings Thursday, updating shareholders on its pipeline progress and initial sales figures for the recently approved vutrisiran (marketed as Amvuttra).
But tucked away near the bottom of its report, the company revealed it would scrap plans to launch a Phase III trial for vutrisiran in the rare Stargardt disease, appearing to blame President Joe Biden’s Inflation Reduction Act in the process.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.